Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (May 2023)
29 slides from Inspiremd's investor presentation, May 23, 2023
Slide 1: Investor Presentation | May 2023
Investor Presentation | May 2023 | INSPIREMD
Slide 2: Disclaimers
Disclaimers Forward Looking Statement This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," “anticipates,” "projects," "predicts," "estimates, i hopes," "potential" or similar words. For example, the Compan
Slide 3: Investment Highlights: Transformational Market Drivers
Investment Highlights : Transformational Market Drivers CGuard EPS Stent Platform utilizing Proprietary Expanding Commercial Footprint MicroNet™ Technology 65) Double-digit market share in 30 served countries (34% in Italy) Highly differentiated platform for treatment of carotid artery Over 40,000 s
Slide 4: Endovascular Procedures: Landscape and InspireMD Potential
Endovascular Procedures: Landscape and InspireMD Potential CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL, CAROTID ARTERY ANEURYSMS, ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE — 30% Surgical* 23% Surgical? 35% Surgical? 19% Surgical* 29de Already have been converted to lovascular proc
Slide 5: Approaches to Treating Carotid Artery Disease
Approaches to Treating Carotid Artery Disease 155,000 Procedures Annually Carotid Artery Stenting (CAS) (20%) Carotid Endarterectomy (CEA) (70%) TCAR (10%) Risk of complications: Risk of complications: Myocardial infarction risk! (heart attack) Procedural and Cranial nerve injury risk" (vertigo, hea
Slide 6: The Problem: Risk of Embolism Following Conventional Carotid Stenting
THE PROBLEM: Risk of Embolism Following Conventional Carotid Stenting (1st generation stents) Approximately 2/3 of neurovascular events (stroke, TIA) occur after the procedure takes place. Pre-Procedure Post-Procedure with Conventional Stent 90% occlusion of | MRI of a pre-existing white Successful
Slide 7: Our Solution: Proprietary MicroNet Technology
OUR SOLUTION: Proprietary MicroNet™ Technology! Conventional Open Cell Stent (15 GEN): Bare or dual layer approach, with plaque protrusion risk An Embolic Prevention System (EPS) for Ultimate Thrombus Protection MicroNet captures and locks thrombus & plaque materials against the arterial wall, deter
Slide 8: MicroNet Scaffolding - Stent Cell Diameters
Mi Scaffolding- Stent Cell Diameters Area Comparison (mm?) 1050p Closed cell stent d $ © s g é og x $ er FF FC SX oo x“ * Bench test results may not necessarily be indicative of clinical performance. . oF KX Stent images approximately at scale but not exact Average in lesion at expanded state & of I
Slide 9: A picture is worth a thousand words ...
A picture is worth a thousand words ... 90% occlusion INSPIREMD
Slide 10: Potential Multi-Billion Dollar Market Opportunity
Potential Multi-Billion Dollar Market Opportunity Current Treated Global Market: > $1.3 billion 407K Global procedures (CEA/CAS/TCAR) to treat HGCS (High Grade Carotid Stenosis) WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical mostly minimally invasive with CGu
Slide 11: Unmatched Foundational Data
Unmatched Foundational Data INSPIREMD
Slide 12: CGuard EPS Yields Superior Clinical Outcomes
CGuard™ EPS Yields Superior Clinical Outcomes JN When compared with Conventional Stents and Surgery (CEA), CGuard trends Superior No stent-related major strokes and 11 minor strokes to date with CGuard in 1,873 patients (Death, Stroke, Myocardial Infarctio 6.00% . in 9 studies (0.6%) 5.20% 4.50% =e
Slide 13: Carotid Solution: Our Well Studied Mesh-Covered Technology
Carotid Solution: Our Well Studied Mesh-Covered Technology More than patients in Clinical Publications & INSPIREMD
Slide 14: Clinical Data Foundation: Evolution to Standard of Care
Clinical Data Foundation: Evolution to Standard of Care YEAR STUDY PUBLICATION HIGHLIGHTS CGUARD'S STANDING (known & ant ated) Journal 2015, CARENET Safety, Efficacy & Neuroprotection over other stents data JACC 2016 PARADIGM All comers population; Excellent clinical results © Guard evaluated as new
Slide 15: CARENET Trial
CARENET Trial First in Man Study- Demonstrated Safety, Efficacy, & Neuroprotection over other stents data Reduction of embolization (50% fewer lesions / 80% less volume with 0 events @ 30 days) ¥ Clinical Support Highlights / Call out 2015-2022 PARADIGM + Extend Opened CARENET study inclusion criter
Slide 16: CARMEN Meta-Analysis (112 Studies, 68K Patients)
mi CARMEN Meta-Analysis (112 Studies, 68K Patients) = Improvements from second-generation stents (SGS) relative to first-generation stents (FGS), but important differences exist amongst the SGS: = Roadsaver limits 30-day events but shows restenosis similar to FGS = Gore performs similarly to FGS = C
Slide 17: US IDE Trial
US IDE Trial INSPIREMD
Slide 18: PMA Trial Design
PMA Trial Design FDA Trial Performance Goal - 11.6% vs European Clinical Trials’ Performance 1.32% (w/ 1 Yr) * Pivotal study objective evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis * Intent to Treat Protocol * Primary Endpoint: Sympt
Slide 19: Roadmap + Milestones
Roadmap + Milestones INSPIREMD
Slide 20: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones Our Expected Key Value Drivers and Strategic Pathways FDA PMA Approval SwitchGuard (TCAR) Launch (U.S. + EU) + FDAPMA Submission * USA Trial Enrollment Complete + Acute Stroke (NGuard) Pivotal + U.S, Commercial Launch * Inclusion of CGuard Prime + China Regulator
Slide 21: TCAR
TCAR INSPIREMD
Slide 22: TCAR Procedure: Reverse Flow
Mm TCAR Procedure : Reverse Flow te amt Cp NY e Clamping (ligation) Guidewire - Reverse flow through surgical CCA clamping and use of CGuard Prime +SwitchGuard INSPIREM9
Slide 23: Corporate
Corporate INSPIREMD
Slide 24: Our Board of Directors
Our Board of Directors Marvin L. Slosman President and CEO Paul Stuka Chairman Michael Berman Director Thomas Kester Director Gary Roubin, M.D.,Ph.D. Director Katie Arnold Director INSPIREMD Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in commerc
Slide 25: Scientific Advisory Board (Multidisciplinary KOLs)
Scientific Advisory Board (Multidisciplinary KOLs) Kenneth Rosenfield, M.D. Chris Metzger , M.D. Interventional Medical Director Cardiologist Cardiologist =i Mass To Pa —_ = General BalladHealth’ ta Cleveland Clinic Brigham INSPIREMD
Slide 26: Active selling CGuard in more than 30 countries
ts . ° Active selling CGuard in more than 30 countries Commercial CGuard Footprint |. over 40K stents sold to date €5) Signed agreement with Chinese distributor. Working toward distribution U.S. Market Investigation Device Exemption (IDE) approval September 2020; US trial initiated Q3 2021 Exploring
Slide 27: Our Robust Intellectual Property Portfolio
Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP ravens a ties eng | USA 16 6 Rest of World 42 11 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel: Kligler and Associates, P.A. INS
Slide 28: Summary Financials
Summary Financials May 22, 2023 NASDAQ Capital Markets NSPR Stock Price $1.90 Average 3 Month Volume 83.5K Shares Outstanding 18.6M Shares Outstanding with Prefunded Warrants 34.2M Market Capitalization with Prefunded Warrants $65M Cash Balance - March 31, 2023* $12.9M Debt $0M * Post financing May
Slide 29: InspireMD
INSPIREM9 ia a (22) Zz i] of 4 a) NY < Zz